BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 27021495)

  • 21. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010.
    Breugelmans JG; Lewis RF; Agbenu E; Veit O; Jackson D; Domingo C; Böthe M; Perea W; Niedrig M; Gessner BD; Yactayo S;
    Vaccine; 2013 Apr; 31(14):1819-29. PubMed ID: 23395587
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tolerance and humoral immune response to the yellow fever vaccine in sickle cell disease children treated with hydroxyurea: a multicentre prospective study.
    Koehl B; Aupiais C; Schinckel N; Mornand P; Odièvre MH; Niakate A; Brousse V; Ithier G; Missud F; Holvoet L; Benkerrou M; Sorge F; Faye A
    J Travel Med; 2021 Apr; 28(3):. PubMed ID: 33550421
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccinations for international travellers travelling from Greece.
    Pavli A; Spilioti A; Lymperi I; Katerelos P; Maltezou HC
    Travel Med Infect Dis; 2013; 11(4):225-30. PubMed ID: 23433917
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of travel medicine practice by yellow fever vaccination centers in England, Wales, and Northern Ireland.
    Boddington NL; Simons H; Launders N; Gawthrop M; Stillwell A; Wong C; Mathewson J; Hill DR
    J Travel Med; 2012; 19(2):84-91. PubMed ID: 22414032
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Suspected YF-AND after yellow fever vaccination in Finland.
    Jääskeläinen AJ; Huhtamo E; Kivioja R; Domingo C; Vene S; Kallio-Kokko H; Niedrig M; Tienari PJ; Vapalahti O
    J Clin Virol; 2014 Nov; 61(3):444-7. PubMed ID: 25223921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advanced age a risk factor for illness temporally associated with yellow fever vaccination.
    Martin M; Weld LH; Tsai TF; Mootrey GT; Chen RT; Niu M; Cetron MS;
    Emerg Infect Dis; 2001; 7(6):945-951. PubMed ID: 11747720
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Yellow fever vaccination status and safety in hemodialysis patients.
    Facincani T; Guimarães MN; De Sousa Dos Santos S
    Int J Infect Dis; 2016 Jul; 48():91-5. PubMed ID: 27208638
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Importation of yellow fever into China: assessing travel patterns.
    Wilder-Smith A; Leong WY
    J Travel Med; 2017 Jul; 24(4):. PubMed ID: 28426111
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Yellow fever 17D vaccine safety and immunogenicity in the elderly.
    Monath TP; Cetron MS; McCarthy K; Nichols R; Archambault WT; Weld L; Bedford P
    Hum Vaccin; 2005; 1(5):207-14. PubMed ID: 17012867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and immunogenicity of yellow fever 17D vaccine in adults receiving systemic corticosteroid therapy: an observational cohort study.
    Kernéis S; Launay O; Ancelle T; Iordache L; Naneix-Laroche V; Méchaï F; Fehr T; Leroy JP; Issartel B; Dunand J; van der Vliet D; Wyplosz B; Consigny PH; Hanslik T
    Arthritis Care Res (Hoboken); 2013 Sep; 65(9):1522-8. PubMed ID: 23554297
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Yellow fever vaccination coverage among children in Brazilian capitals.
    Veras MA; Flannery B; de Moraes JC; da Silva Teixeira AM; Luna EJ;
    Vaccine; 2010 Sep; 28(39):6478-82. PubMed ID: 20674878
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Yellow fever vaccination: how much is enough?
    Massad E; Coutinho FA; Burattini MN; Lopez LF; Struchiner CJ
    Vaccine; 2005 Jun; 23(30):3908-14. PubMed ID: 15917112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenicity of a primary yellow fever vaccination under low-dose methotrexate therapy-a prospective multi-centre pilot study1.
    Bühler S; Jaeger VK; Eperon G; Furrer H; Fux CA; Jansen S; Neumayr A; Rochat L; Schmid S; Schmidt-Chanasit J; Staehelin C; de Visser AW; Visser LG; Niedrig M; Hatz C
    J Travel Med; 2020 Sep; 27(6):. PubMed ID: 32729905
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Late vaccination against yellow fever of travelers visiting endemic countries.
    Krief I; Goldblatt JG; Paz A; Potasman I
    Travel Med Infect Dis; 2006 Mar; 4(2):94-8. PubMed ID: 16887731
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil.
    Galler R; Pugachev KV; Santos CL; Ocran SW; Jabor AV; Rodrigues SG; Marchevsky RS; Freire MS; Almeida LF; Cruz AC; Yamamura AM; Rocco IM; da Rosa ES; Souza LT; Vasconcelos PF; Guirakhoo F; Monath TP
    Virology; 2001 Nov; 290(2):309-19. PubMed ID: 11883195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of yellow fever in persons traveling to the tropics.
    Monath TP; Cetron MS
    Clin Infect Dis; 2002 May; 34(10):1369-78. PubMed ID: 11981733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. National review of reported Yellow fever vaccine incidents in the UK.
    Gnanadurai R; Campos-Matos I; Kanagarajah S; Geary K; Simons H; Patel D
    Travel Med Infect Dis; 2022; 47():102289. PubMed ID: 35227862
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Co-administration of live measles and yellow fever vaccines and inactivated pentavalent vaccines is associated with increased mortality compared with measles and yellow fever vaccines only. An observational study from Guinea-Bissau.
    Fisker AB; Ravn H; Rodrigues A; Østergaard MD; Bale C; Benn CS; Aaby P
    Vaccine; 2014 Jan; 32(5):598-605. PubMed ID: 24325827
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Booster dose after 10 years is recommended following 17DD-YF primary vaccination.
    Campi-Azevedo AC; Costa-Pereira C; Antonelli LR; Fonseca CT; Teixeira-Carvalho A; Villela-Rezende G; Santos RA; Batista MA; Campos FM; Pacheco-Porto L; Melo Júnior OA; Hossell DM; Coelho-dos-Reis JG; Peruhype-Magalhães V; Costa-Silva MF; de Oliveira JG; Farias RH; Noronha TG; Lemos JA; von Doellinger Vdos R; Simões M; de Souza MM; Malaquias LC; Persi HR; Pereira JM; Martins JA; Dornelas-Ribeiro M; Vinhas Ade A; Alves TR; Maia Mde L; Freire Mda S; Martins Rde M; Homma A; Romano AP; Domingues CM; Tauil PL; Vasconcelos PF; Rios M; Caldas IR; Camacho LA; Martins-Filho OA
    Hum Vaccin Immunother; 2016; 12(2):491-502. PubMed ID: 26360663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Yellow Fever Vaccination of a Primary Vaccinee During Adalimumab Therapy.
    Nash ER; Brand M; Chalkias S
    J Travel Med; 2015; 22(4):279-81. PubMed ID: 25922988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.